公开(公告)号：US20240140922A1

公开(公告)日：2024-05-02

申请号：US18236560

申请日：2023-08-22

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Samuel Bartlett ,  Joseph D. Panarese ,  Sourav Ghorai ,  Nathaniel Thomas Kenton ,  Sean Rafferty ,  Jonathan Thielman ,  Peilin Xu ,  Bin Wang ,  William Cassels ,  Scott Mitchell ,  Yat Sun Or

IPC: C07D285/36 ,  A61P31/20 ,  C07D337/08 ,  C07D417/04 ,  C07D417/08 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04 ,  C07D513/04 ,  C07F9/6536

CPC classification number: C07D285/36 ,  A61P31/20 ,  C07D337/08 ,  C07D417/04 ,  C07D417/08 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04 ,  C07D513/04 ,  C07F9/6536

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:




which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US11970473B2

公开(公告)日：2024-04-30

申请号：US17710485

申请日：2022-03-31

Applicant: Arkansas State University—Jonesboro

Inventor： Mohammad Abrar Alam

IPC: C07D277/84 ,  A61K31/428 ,  A61P31/04 ,  C07D417/04 ,  C07D417/06 ,  C07D417/10 ,  C07D417/12

CPC classification number: C07D277/84 ,  A61P31/04 ,  C07D417/04 ,  C07D417/06 ,  C07D417/10 ,  C07D417/12

Abstract: Nootkatone derivatives comprising a fused thiazole ring and methods of using the same are disclosed herein.

公开(公告)号：US11958840B2

公开(公告)日：2024-04-16

申请号：US17702718

申请日：2022-03-23

Applicant: Denali Therapeutics Inc.

Inventor： Robert A. Craig, II ,  Javier de Vicente Fidalgo ,  Anthony A. Estrada ,  Jianwen A. Feng ,  Brian M. Fox ,  Maksim Osipov ,  Arun Thottumkara

IPC: C07D413/04 ,  C07D271/113 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D493/08

CPC classification number: C07D413/04 ,  C07D271/113 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D493/08

Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.

公开(公告)号：US20240101536A1

公开(公告)日：2024-03-28

申请号：US18339516

申请日：2023-06-22

Applicant: Terns Pharmaceuticals, Inc.

Inventor： F. Anthony ROMERO ,  Thorsten A. KIRSCHBERG ,  Randall HALCOMB ,  Yingzi XU

IPC: C07D403/04 ,  C07D413/04 ,  C07D235/16 ,  C07D409/14 ,  C07D417/04 ,  A61P35/00 ,  C07D471/04 ,  C07D513/04 ,  C07D405/14 ,  C07D498/04 ,  C07D403/14

CPC classification number: C07D403/04 ,  C07D413/04 ,  C07D235/16 ,  C07D409/14 ,  C07D417/04 ,  A61P35/00 ,  C07D471/04 ,  C07D513/04 ,  C07D405/14 ,  C07D498/04 ,  C07D403/14

Abstract: Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease.

公开(公告)号：US11932798B2

公开(公告)日：2024-03-19

申请号：US16732739

申请日：2020-01-02

Applicant: FUJIFILM Corporation

Inventor： Satoshi Shimamura ,  Daisuke Hayashi ,  Keita Takahashi

IPC: C09K19/38 ,  C07C69/753 ,  C07D339/06 ,  C07D417/04 ,  C08F20/38 ,  C09K19/34 ,  C09K19/56 ,  G02B5/30 ,  C09K19/04

CPC classification number: C09K19/3861 ,  C07C69/753 ,  C07D339/06 ,  C07D417/04 ,  C08F20/38 ,  C09K19/3491 ,  C09K19/3497 ,  C09K19/56 ,  G02B5/3016 ,  C08F2800/20 ,  C09K2019/0448 ,  C09K2323/03 ,  C09K2323/031 ,  C09K2323/035 ,  G02B5/3083

Abstract: The present invention has an object to provide a polymerizable liquid crystal compound used for formation of an optically anisotropic film having excellent reciprocal wavelength dispersion and moisture-heat resistance, a polymerizable liquid crystal composition, an optically anisotropic film, an optical film, a polarizing plate, and an image display device. The polymerizable liquid crystal compound of the present invention is a polymerizable liquid crystal compound represented by Formula (1), in which a Clog P value of a group represented by Ar in Formula (1) is 4.3 or more and less than 7.0.

公开(公告)号：US11932635B2

公开(公告)日：2024-03-19

申请号：US18059232

申请日：2022-11-28

Applicant: Kymera Therapeutics, Inc.

Inventor： Nello Mainolfi ,  Nan Ji ,  Arthur F. Kluge

IPC: C07D211/88 ,  C07D239/22 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D417/04 ,  C07D211/88 ,  C07D239/22 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D413/04 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

公开(公告)号：US20240059961A1

公开(公告)日：2024-02-22

申请号：US18447907

申请日：2023-08-10

Applicant: Promega Corporation

Inventor： Ian Marozas ,  Zhiyang Zeng ,  Wenhui Zhou ,  James J. Cali ,  Mike Valley ,  Jolanta Vldugiriene

IPC: C09K11/06 ,  C07D417/04 ,  C07F15/00 ,  C08G77/04 ,  G01N21/64 ,  G01N33/497

CPC classification number: C09K11/06 ,  C07D417/04 ,  C07F15/0086 ,  C08G77/04 ,  G01N21/6428 ,  G01N33/497 ,  C09K2211/185 ,  G01N2021/6439

Abstract: Provided herein are polysiloxane matrices and biocompatible films thereof for the detection of oxygen. In particular, oxygen-sensitive fluorophores embedded within polysiloxane matrices are utilized for detection of oxygen consumption rate in living cells.

公开(公告)号：US20240052235A1

公开(公告)日：2024-02-15

申请号：US18258738

申请日：2021-12-14

Applicant: Essilor International

Inventor： Claudine BIVER ,  Fabien BERIT-DEBAT ,  Samuel ARCHAMBEAU ,  Stuart AIKEN ,  Georgina K. ARMITAGE ,  Thomas D. BROADBENT ,  Daniel L. CROSSLEY ,  Christopher D. GABBUTT ,  Bernard Mark HERON

IPC: C09K9/02 ,  C07D417/04 ,  C07D401/04 ,  C07D471/04 ,  C07D401/14 ,  C07D421/04 ,  C07D413/04

CPC classification number: C09K9/02 ,  C07D417/04 ,  C07D401/04 ,  C07D471/04 ,  C07D401/14 ,  C07D421/04 ,  C07D413/04 ,  C09K2211/1018 ,  C09K2211/1007 ,  G02F1/0018

Abstract: The invention relates to a group of novel electrochromic compounds. More specifically, it relates to benzazoles and condensed azole compounds substituted with one or several pyridinium rings and the use of these compounds as a variable transmittance medium for the manufacture of an optical article, such as an ophthalmic lens.

公开(公告)号：US20240043389A1

公开(公告)日：2024-02-08

申请号：US18043441

申请日：2021-09-01

Applicant: Albert Einstein College of Medicine

Inventor： Evripidis Gavathiotis

IPC: C07D231/46 ,  C07D401/04 ,  C07D417/04 ,  A61K31/635 ,  A61P7/04 ,  A61K31/4152 ,  A61K31/4439 ,  A61K31/427 ,  A61K31/4155 ,  A01N1/02

CPC classification number: C07D231/46 ,  C07D401/04 ,  C07D417/04 ,  A61K31/635 ,  A61P7/04 ,  A61K31/4152 ,  A61K31/4439 ,  A61K31/427 ,  A61K31/4155 ,  A01N1/0226

Abstract: This disclosure provides novel compounds and methods for inhibiting BAX activity and BAX-mediated apoptosis, as well as compounds and methods for treating or preventing BAX-mediated disorders.

公开(公告)号：US11891369B2

公开(公告)日：2024-02-06

申请号：US16861166

申请日：2020-04-28

Applicant: SRX Cardio, LLC

Inventor： Anjali Pandey ,  Simeon Bowers ,  Thomas E. Barta ,  Jonathan William Bourne

IPC: A61K31/4709 ,  C07D295/073 ,  C07D401/04 ,  C07D403/04 ,  C07D211/18 ,  C07D211/26 ,  C07D211/46 ,  C07D211/54 ,  C07D211/58 ,  C07D295/195 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/02 ,  C07D417/04 ,  C07D417/14 ,  C07D471/08

CPC classification number: C07D295/073 ,  C07D211/18 ,  C07D211/26 ,  C07D211/46 ,  C07D211/54 ,  C07D211/58 ,  C07D295/195 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D407/02 ,  C07D417/04 ,  C07D417/14 ,  C07D471/08

Abstract: The present disclosure relates to novel compounds, methods, and compositions capable of binding to PCSK9, thereby modulating PCSK9 proprotein convertase enzyme activity, for treatment of a disease or condition mediated, at least in part, by PCSK9. The compounds of the disclosure include compounds Formula (I).